Efficacy and Safety of Privigen®in Patients With Chronic Inflammatory Demyelinating Polyneuropathy: Results of a Prospective, Single-Arm, Open-Label Phase III Study (The PRIMA Study)

Journal of the Peripheral Nervous System - United Kingdom
doi 10.1111/jns5.12017
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Efficacy, Safety and Pharmacokinetics of Subcutaneous Azacitidine in Chinese Patients With Higher Risk Myelodysplastic Syndromes: Results From a Multicenter, Single-Arm, Open-Label Phase 2 Study

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2017English

Mechanisms of IVIG Efficacy in Chronic Inflammatory Demyelinating Polyneuropathy

Journal of Clinical Immunology
AllergyImmunology
2010English

Chronic Inflammatory Demyelinating Polyneuropathy

2020English

Safety and Efficacy of Regorafenib in Patients With Treatment-Refractory Metastatic Colorectal Cancer in Turkey: The Single-Arm, Open-Label REGARD Study

BMJ Open
Medicine
2020English

Efficacy and Safety of Octanorm (Cutaquig®) in Adults With Primary Immunodeficiencies With Predominant Antibody Deficiency: A Prospective, Open-Label Study

Immunotherapy
OncologyAllergyImmunology
2020English

Clinical Efficacy and Safety of “Vasavaleha” in the Management of Stable Chronic Bronchitis: A Prospective Open Label Multicenter Study

Journal of Research in Ayurvedic Sciences
2017English

An Open Label Study to Evaluate Safety and Efficacy of Unex® Capsules in Patients With Urinary Disorders

Journal of Ayurveda Medical Sciences
2018English

Glomerulonephritis Associated With Chronic Inflammatory Demyelinating Polyneuropathy

Renal Failure
MedicineNephrologyCritical CareIntensive Care Medicine
2006English

A Study Protocol for Evaluating the Efficacy and Safety of Skin Electrical Stimulation for Leber Hereditary Optic Neuropathy: A Single-Arm, Open-Label, Non-Randomized Prospective Exploratory Study

Clinical Ophthalmology
Ophthalmology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy